Our proprietary platform technology supports the expansion of new drug pipelines while an open innovation strategy allows us to promptly advance into the clinic. With our lead pipeline, we are fast-tracking to become a clinical-stage biotech company.
Two track strategy of R&D and Commercialization
좌우로 스크롤 하시면 전체 내용을 확인할 수 있습니다.
President(CEO) : Gyongsik Ha
260, Changnyong-daero, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea